| Ytd | ||
| 1y |
| Open | 0.88 | Prev Close | 0.88 | Low | 0.87 | High | 0.88 | Mkt Cap | 53.65M |
| Vol | 53.69K | Avg Vol | 855.96K | EPS | -1.07 | P/E | -0.82 | Forward P/E | -0.69 |
| Beta | 1.64 | Short Ratio | 8.81 | Inst. Own | 32.67% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.80 | 200-d Avg | 0.90 | 1yr Est | 2.25 |
KRON News
Kronos Bio completed its sale to Concentra Biosciences for 57 cents a share in cash plus contingent
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
NEW YORK , May 1, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Kronos (Nasdaq: KRON) for possible breac
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a
SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq
– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobel
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammat
Piper Sandler analyst Edward Tenthoff downgraded Kronos Bio to Neutral from Overweight with a price
Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus
– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tum
– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV)
– KB-7898, a p300 KAT inhibitor, is the Company's first development candidate for autoimmune disease
– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the a
– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of
The heavy selling pressure might have exhausted for Kronos Bio (KRON) as it is technically in overso
SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq
Kronos Bio (KRON) is technically in oversold territory now, so the heavy selling pressure might have
Kronos Bio (KRON) possesses the right combination of the two key ingredients for a likely earnings b
During Thursday's session, 406 companies made new 52-week lows.
During Thursday's session, 99 companies made new 52-week lows.
OnFriday, 143 stocks hit new 52-week lows.
On Monday, 79 companies reached new 52-week lows.
OnThursday, 137 stocks made new 52-week lows.
On Monday, 413 companies reached new 52-week lows.
On Tuesday, 838 companies hit new 52-week lows.
On Friday, 404 stocks made new 52-week lows.
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral t
During Monday's trading, 1214 companies set new 52-week lows.
On Wednesday, 215 companies set new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
During Wednesday's trading, 435 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
On Friday, 431 companies hit new 52-week lows.
On Monday, 524 stocks hit new 52-week lows.
On Friday, 368 stocks hit new 52-week lows.
On Friday, 313 companies hit new 52-week lows.
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insid
On Friday, 209 companies set new 52-week lows.
During Friday's session, 445 companies made new 52-week lows.
Gainers electroCore, Inc. (NASDAQ: ECOR) shares jumped 64% to settle at $0.88 on Wednesday after
On Friday morning, 155 companies achieved new lows for the year.